|
|
Article: Omalizumab controls severe allergic asthma.(Pulmonary Medicine)
- Article from:
- Family Practice News
- Article date:
- April 15, 2006
- Author:
CopyrightCOPYRIGHT 2006 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Miami -- Omalizumab maintained control of severe allergic asthma and reduced the need for inhaled corticosteroids during 3 years of treatment in an analysis of data from a 52-week open-label extension study.
The findings extend the results of previous studies by showing that asthma control and a favorable safety and tolerability profile were maintained during long-term treatment with the anti-IgE monoclonal antibody, Dr. Jacques Hebert and associates reported in a poster at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.
The study was supported by Genentech Inc. and Novartis Pharmaceuticals Corp., which comarket omalizumab ...